Positive data from CTI BioPharma By: MarketMinute » Stock News June 01, 2015 at 06:54 AM EDT CTI BioPharma Corp. (Nasdaq: CTIC) reported positive data from a Phase 3 registration-directed trial of pacritinib to treat myelofibrosis lifting the stock price 39 cents to $2.33.